Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040973 · ClinicalTrials.gov registry record · Phase 2
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
A Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 15
- Study locations
NCT03040973: Active Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent, sponsored by Novartis Pharmaceuticals.
NCT03040973 is a Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03040973, a Phase 2 study of Advanced Solid Tumors Which Are cMET-dependent, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study
Primary Outcome
Collection of adverse events and serious adverse events at every visit. Safety assessment will be performed and include local laboratory test monitoring in addition to local standard of care assessments.
Conditions Studied
Interventions
- DRUG Capmatinib
- DRUG Osimertinib
- DRUG Gefitinib
- DRUG Nazartinib
Study Locations (15)
Other
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Copenhagen
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Seoul
- Novartis Investigative Site - Madrid
Massachusetts
- Massachusetts General Hospital - Boston
Alberta
- Novartis Investigative Site - Edmonton
Shanghai Municipality
- Novartis Investigative Site - Shanghai
Yunnan
- Novartis Investigative Site - Kunming
Cote D Or
- Novartis Investigative Site - Dijon
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
MI
- Novartis Investigative Site - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 2 |
What the registry record for NCT03040973 still lists
NCT03040973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Advanced Solid Tumors Which Are cMET-dependent appearing as the primary indexed condition, and to 4 interventions - of which Capmatinib is the first listed.
NCT03040973 lists 15 locations in 10 states (Other, Massachusetts, Alberta).
Frequently Asked Questions
What is clinical trial NCT03040973 about?
NCT03040973 is a clinical study titled "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone". The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment a...
What is the current status of trial NCT03040973?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-08-23. Estimated completion is 2027-07-30.
What conditions does trial NCT03040973 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Which Are cMET-dependent.
What interventions are being tested in trial NCT03040973?
The interventions under investigation include: Capmatinib (DRUG), Osimertinib (DRUG), Gefitinib (DRUG), Nazartinib (DRUG).
Who is sponsoring clinical trial NCT03040973?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03040973 being conducted?
This trial has 15 study locations across Massachusetts, Alberta, Shanghai Municipality, Yunnan, Cote D Or. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03040973's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI